Candace Kendle started Kendle International as a small, private start-up in 1981. Today, the firm employs about 3,000, is traded on the Nasdaq exchange, and does business in 90 countries. Kendle is a clinical research organization, providing the full range of early- to late-stage clinical development services for the biopharmaceutical industry. Most of the world's top 50 pharmaceutical companies are among its customers. Kendle helps pharmaceutical firms get drugs to market by providing a variety of clinical development services, ranging from “first-in-human” studies through market launch and surveillance. Its revenues grew 40 percent in 2007 to $397 million.
Kendle has 47 offices in 27 countries across six continents, with experience spanning 90 countries around the world. Its employees contributed to the development of more than 600 new compounds last year, working with more than 300 customers. The company is focused on clinical trials in the top five therapeutic areas expected to represent 70 percent of research and development spending by 2009: cardiology, oncology, antibiotics and antivirals, central nervous system and arthritis/inflammation. It expects another year of growth in 2008, projecting revenues of between $450 million and $460 million, which would be 13 to 16 percent growth over 2007.
Kendle was recognized as the “Top Clinical Research Organization to Work With” in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites and as the “Best Contract Research Organization” in November 2006 by an independent panel for Scrip World Pharmaceutical News. Kendle just announced the promotion of Simon S. Higginbotham to the president. Chris Bergen, who previously had served as president and chief operating officer, will continue as chief operating officer.
"We are united in a common passion to bring life-saving and life-enhancing drugs to market for the benefit of patients worldwide," says Candace Kendle.
Photo courtesy of NASDAQ